drugset / Trial / NCT01367314
Safety and Efficacy of Topical NVC-422 Gel in Impetigo
Phase 2
Completed
129 enrolled
NovaBay Pharmaceuticals, Inc.
International Dermatology Research, Inc. · collabNovum Pharmaceutical Research Services · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind study comparing 0.1% NVC-422, 0.5% NVC-422 and 1.5% NVC-422 topical gel in children with impetigo.
Timeline
- Start
- 2009-08
- Primary completion
- 2010-05
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NVC-422 | Unknown | 0.1 % | Topical |
| Subject | NVC-422 | Unknown | 0.5 % | Topical |
| Subject | NVC-422 | Unknown | 1.5 % | Topical |